Telomir制药公司获得100万美元的投资,表明投资者信心很强。 Telomir Pharmaceuticals secures $1 million investment, signaling strong investor confidence.

Telomir制药公司获得了100万美元的投资,每股7美元,比最近股票价格增加了20%。 Telomir Pharmaceuticals secured a $1 million investment at $7 per share, marking a 20% increase over its recent stock price. 这一交易涉及没有逮捕证的有限共同股票,表明投资者信心很强。 This deal, involving restricted common stock without warrants, signals strong investor confidence. 同时,Scilex控股公司正在组建一个合资企业,对肥胖症和阿尔茨海默氏症进行可能的新的口服治疗,目前正处于第二阶段临床试验阶段。 Meanwhile, Scilex Holding Company is forming a joint venture for a potential new oral treatment for obesity and Alzheimer's, currently in phase 2 clinical trials.